First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014

Dateline City:

CHICAGO

Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients
Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024)
Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Merck’s Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data evaluating pembrolizumab
(MK-3475), Merck’s investigational anti-PD-1 antibody, as initial
therapy in patients with PD-L1 positive, advanced non-small cell lung
cancer (NSCLC).
Language:

English

Contact:

MerckMedia Contacts:Ian McConnell, [phone]orClaire Mulhearn, [phone]orInvestor Contacts:Carol Ferguson, [phone]orJustin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: ...

Source: Merck.com - Corporate News - June 2, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news